Dendritic cell derived exosomes loaded neoantigens for personalized cancer immunotherapies

• DOI: 10.1016/j.jconrel.2022.11.053
• Publication Date: 2022-12-07T18:09:40Z
• Authors: Ji Li; Jiajia Li; Yiwei Peng; Yitian Du; Zhenzhen Yang; Xianrong Qi
• Keywords: 0303 health sciences; 03 medical and health sciences; Antigens, Neoplasm; Neoplasms; T-Lymphocytes; Humans; Dendritic Cells; Immunotherapy; Exosomes; Melanoma; Cancer Vaccines; 3. Good health

Despite the promising potential of cancer vaccine, their efficacy has been limited in clinical trials and improved methods are urgently needed. Here we designed a nanovaccine platform that contains dendritic cell derived exosomes carriers and patient-specific neoantigens for individualized immunotherapies. The nanovaccine exhibited convenient cargo loading and prolonged cargo transportation to the lymph nodes, followed by eliciting potent antigen specific broad-spectrum T-cell and B-cell-mediated immune responses with great biosafety and biocompatibility. Strikingly, delivery of neoantigen-exosome nanovaccine significantly prohibited tumor growth, prolonged survival, delayed tumor occurrences with long-term memory, eliminated the lung metastasis in the therapeutic, prophylactic and metastatic B16F10 melanoma as well as therapeutic MC-38 models, respectively. Additionally, exosome-based nanovaccine demonstrated synergistic antitumor response superior to liposomal formulation due to presence of exosomal proteins. Collectively, our research indicated improved strategies for cell free vaccines and suggested exosome-based nanoplatform for cancer immunotherapy and personalized nanotechnology. These findings represent a powerful pathway to generate individualized nanovaccine rapidly for clinical application.